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ABSTRACT: Three new members of the angucycline class of
antibiotics, pseudonocardones A−C( 1−3), along with the
known antibiotics 6-deoxy-8-O-methylrabelomycin (4) and X-
14881 E (5) have been isolated from the culture of a
Pseudonocardia strain associated with the fungus-growing ant
Apterostigma dentigerum. Compounds 4 and 5 showed
antibiotic activity against Bacillus subtilis 3610 and liver-stage
Plasmodium berghei, while 1−3 were inactive or only weakly
active in a variety of biological assays. Compound 5 also
showed moderate cytotoxicity against HepG2 cells.
B
acteria of the genus Pseudonocardia associate with fungus-
growing ants
1 and produce antibiotics that presumptively
play a role in suppressing fungal pathogens in ants’ gardens.
2,3
While Pseudonocardia belongs to the Actinomycetales, which
are well known for their remarkable ability to produce bioactive
secondary metabolites, relatively few natural products have
been described from Pseudonocardia spp. Antibiotics discovered
from Pseudonocardia spp. include dentigerumycin,
3 pseudono-
cardians A and B,
4 phenazostatin D,
5 and NPP.
6 Of these, only
dentigerumycin was discovered from a Pseudonocardia strain
associated with fungus-growing ants, and these symbionts likely
have many more undiscovered natural products. As part of our
ongoing eﬀort to explore natural products from bacterial
symbionts,
3,7−9 we have investigated the natural products from
Pseudonocardia sp. EC080529-01, isolated from the cuticle of
the fungus-growing ant Apterostigma dentigerum.
10 This strain
produces three new members of the angucycline family of
antibiotics,
11 pseudonocardones A (1), B (2), and C (3), along
with the known antibiotics 6-deoxy-8-O-methylrabelomycin
(4)
12 and X-14881 E (5).
13
Pseudonocardia sp. EC080529-01 was grown on solid ISP-2
medium, and the agar was extracted with EtOAc followed by
MeOH. HPLC-MS analysis of the EtOAc extract revealed two
peaks with interesting UV spectra (λmax at 381 and 410 nm,
respectively). HPLC-MS analysis of the MeOH extract revealed
three additional polar peaks with λmax at 348 nm, 388, and 409
nm, respectively. Production cultures of Pseudonocardia sp.
EC080529-01 were grown on solid ISP-2 medium and
extracted with EtOAc followed by MeOH. The EtOAc extract
was puriﬁed (see Experimental Section) to give 6-deoxy-8-O-
methylrabelomycin (4, 8.3 mg) and X-14881 E (5, 3.5 mg).
The MeOH extract was puriﬁed (see Experimental Section) to
give pseudonocardones A (1, 2.0 mg), B (2, 0.9 mg), and C (3,
1.8 mg). The known compounds 4 and 5 were identiﬁed by 1D
and 2D NMR spectroscopy, and their structures were
conﬁrmed by comparison of their spectroscopic data with the
literature values.
12,13
Pseudonocardone A (1) gave a peak in the HRESI(+) MS
consistent with a molecular formula of C26H24O10. The NMR
data (Figures 1 and 2 and Table 1) obtained for 1 indicated
that it was related to the angucycline family of antibiotics and
that it was similar in structure to 5. The peak in the UV
spectrum of 5 at λmax = 410 nm had shifted to λmax = 348 nm.
While compound 5 showed two carbon resonances typical of a
quinone (δC 191.3 and 182.0), compound 1 showed only one
carbon resonance in this range (δC 186.0). Instead, compound
1 showed a signal for an oxygenated methine resonance (δC
66.5; δH 6.93). This methine resonance showed HMBC
correlations to C-6a (δC 132.5), C-7a (δC 120.8), C-11 (δC
123.8), C-11a (δC 147.7), C-12a (δC 139.6), and C-12b
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hydroquinone tautomer rather than a quinone as found in 5.
Additional signals were present in the NMR spectra of 1 that
could not be attributed to the angucycline core. Subtracting the
atoms accounted for by the hydroquinone substructure showed
that the remaining fragment had to account for C6H9O6.A
series of oxygenated methine resonances in the HSQC
spectrum (δC 73.1−77.1 and δH 3.63−4.16) and a resonance
typical of an anomeric carbon (δC 103.8 and δH 5.23) suggested
that 1 was glycosylated. An HMBC correlation from the
anomeric proton at δH 5.23 to δC 156.9 (C-1) showed that 1
was glycosylated at the oxygen atom attached to C-1. A series of
COSY and HMBC correlations (Figure 2) revealed that the
sugar was a hexose. Finally, HMBC correlations from δH 3.76
(H-4′) and 4.16 (H-5′) to a carbonyl carbon at δC 173.0 (C-6′)
showed that the sugar had been oxidized to the carboxylic acid
at C-6′.
The relative conﬁguration of the sugar residue in 1 was
determined by coupling constants and a NOESY experiment.
Large coupling constants (J values ranged from 7.6 to 10.0 Hz;
see Table 1) indicated that all of the protons must be axial, and
therefore the sugar corresponds to β-glucuronic acid. This
assignment was supported by NOESY correlations between δH
5.23 (H-1′) and δH 3.63 (H-3′), between δH 5.23 (H-1′) and
δH 4.16 (H-5′), between δH 3.93 (H-2′) and δH 3.76 (H-4′),
and between δH 3.63 (H-3′) and δH 4.16 (H-5′) (Figure 3).
The absolute conﬁguration of the sugar moiety was not
determined. The absolute conﬁguration of C-12 was also not
determined.
Pseudonocardone B (2) gave a peak in the HRESI(+) MS
consistent with a molecular formula of C26H22O10.T h e
molecular formula of 2 diﬀered from that of 1 by the loss of
Figure 1. Key COSY and HMBC correlations in the aglycone moiety
of pseudonocardone A (1).
Figure 2. Key COSY and HMBC correlations in the sugar moiety of
pseudonocardone A (1).
Table 1. 1H and 13C NMR Data for Pseudonocardones A (1), B (2), and C (3) Recorded in CD3OD at 600 MHz
pseudonocardone A (1) pseudonocardone B (2) pseudonocardone C (3)
position δC δH (J in Hz) δC δH (J in Hz) δC δH (J in Hz)
1 156.9 154.7
2 114.7 7.21, s 115.8 7.25, s 144.7
3 140.5 141.8 134.7
4 124.0 7.37, s 122.9 7.45, s 120.3 6.95, s
4a 139.4 135.4 131.9
5 130.0 7.78, d (8.8) 134.4 8.06, d (8.2) 133.0 8.97, d (9.4)
6 124.5 8.10, d (8.2) 123.0 8.16, d (8.8) 122.8 8.17, d (8.8)
6a 132.5 135.0 137.1
7 186.0 182.8 183.1
7a 120.8 120.8 119.9
8 161.1 160.3 160.5
9 112.8 7.13, d (8.2) 118.3 7.47, d (8.8) 119.3 7.49, d (8.2)
10 136.0 7.64, t (7.9) 136.7 7.78, t (7.9) 136.5 7.75, t (7.9)
11 123.8 7.34, d (8.6) 119.3 7.62, d (7.6) 121.1 7.78, d (7.0)
11a 147.7 139.9 138.4
12 66.5 6.93, s 189.5 190.8
12a 139.6 138.8 133.2
12b 121.6 119.5 121.0
13 21.8 2.47, s 21.6 2.52, s 17.0 2.50, s
14 49.4 3.95, s 56.4 4.01, s 56.6 3.99, s
1′ 103.8 5.23, d (7.6) 101.8 5.26, d (7.0) 106.6 4.76, d (7.6)
2′ 75.0 3.93, t (8.8) 74.5 3.58, m 75.1 3.71, dd (9.1, 7.9)
3′ 77.1 3.63, t (9.4) 77.1 3.59, m 77.2 3.50, t (9.1)
4′ 73.1 3.76, t (9.4) 72.6 3.60, m 72.9 3.63, t (9.4)
5′ 76.7 4.16, d (10.0) 76.1 3.98, d (9.4) 76.8 3.55, d (10.0)
6′ 173.0 172.6 173.5
Figure 3. NOESY correlations in the sugar moiety of pseudono-
cardone A (1).
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signiﬁcantly from that of 1, with the low-energy λmax having
shifted from 348 nm in 1 to 388 nm in 2. The NMR data
obtained for 2 were very similar to that of 1, suggesting that the
compounds were closely related. The NMR signals correspond-
ing to the C-12 oxygenated methine present in 1 were absent
from the NMR spectra of 2. Instead, the resonance at δH 7.62
(H-11) showed an HMBC to a carbon at δC 189.5 (C-12),
typical of a quinone carbon, revealing that 2 is the quinone
analogue of 1.
Pseudonocardone C (3) gave a peak in the HRESI(+) MS
consistent with a molecular formula of C26H22O11.T h e
molecular formula of 3 diﬀered from the molecular formula
of 2 by the addition of an oxygen atom. The UV and NMR data
obtained for 3 were very similar to that of 2, suggesting that
they are closely related. The aromatic singlet present in 2 at δH
7.25 (H-2) was absent in the NMR spectrum of 3, and the
other aromatic singlet at δH 7.45 (H-4) was shifted upﬁeld to
δH 6.95 (H-4) in 3. The methyl resonance at δH 2.50 showed an
HMBC correlation to a downﬁeld carbon at δC 144.7 (C-2),
suggesting that C-2 was substituted with an oxygen atom. An
HMBC correlation from the anomeric proton at δH 4.76 (H-1′)
to C-2 showed that the sugar moiety was attached to C-2
instead of to C-1 as found in 1 and 2. The lack of protons
within three bonds from C-1 made the assignment of this
position impossible to determine from the HMBC data.
However, in order to satisfy the molecular formula of 3, C-1
must be oxygenated as it is in 1, 2, and 5.
Compounds 1−5 were tested for antibiotic activity against
Escherichia coli K12, Bacillus subtilis 3610, Candida albicans, and
Saccharomyces cerevisiae. Compounds 4 and 5 were active
against B. subtilis 3610 with MIC values of 25 and 3.13 μg/mL,
respectively. None of the compounds showed any activity
against E. coli, C. albicans,o rS. cerevisiae at concentrations as
high as 50 μg/mL. Compounds 1−5 were also tested in a liver-
stage malaria assay recently developed in one of our
laboratories.
14 Compounds 4 and 5 were active against liver-
stage Plasmodium berghei with IC50 values of 18.5 and 3.0 μM,
respectively. Finally, compounds 1−5 were tested for
cytotoxicity against HepG2 cells. Compound 5 was active
against HepG2 cells with an IC50 value of 36.1 μM. The
glycoside analogues (1−3) were completely inactive against B.
subtilis, E. coli, C. albicans, S. cerevisiae, and HepG2 cells at
concentrations as high as 50 μg/mL and showed only weak
activity against liver-stage P. berghei with IC50 values of 38, 50,
and >100 μM, respectively. The lack of activity for the
glycosylated analogues provides insight into the structure−
activity relationships of this family of compounds. A
comparison of the activity of 2 with that of 5 shows that
adding the glucuronic acid moiety at C-1 completely abolishes
cytotoxic and antibiotic activity. Glycosylation of antibiotics has
been proposed as one possible mechanism of self-resist-
ance,
15,16 and this might explain the lack of biological activity
observed for 1−3.
■ EXPERIMENTAL SECTION
General Experimental Procedures. An Agilent 1200 Series
HPLC system equipped with a diode array detector and a
Phenomenex C18 column (5 μm, 250 × 21.2 mm) was used for
preparative HPLC. For HPLC-MS analysis, an Agilent HPLC system
equipped with a diode array detector and a 6130 Series quadrupole
mass spectrometer was used with a Phenomenex C18 (5 μm, 100 × 4.6
mm) column. The following gradient was used for HPLC-MS analysis:
0−5 min, isocratic 10% CH3CN + 0.1% formic acid; 5−25 min, linear
gradient from 10% CH3CN + 0.1% formic acid to 100% CH3CN +
0.1% formic acid. NMR spectra were recorded in CD3OD (for
compounds 1−4)o rC D 2Cl2 (for compound 5) at 600 MHz and
referenced to the internal solvent peak at δH 3.30 and δC 49.0 or δH
5.32 and δC 53.8, respectively. High-resolution mass spectrometry
(HR-MS) was performed at the University of Illinois Urbana−
Champaign Mass Spectrometry Facility.
Isolation of Pseudonocardia sp. EC080529-01. An ant colony
of A. dentigerum was collected from Pipeline Road, Panama, on May
29, 2008, and placed in a sterile Petri dish with moist cotton. After
allowing the nest to stabilize for a few days, the Pseudonocardia
symbiont from this colony was isolated directly from the mesoternal
lobe of a worker by scraping bacteria oﬀ the cuticle of the ant using a
sterile scalpel and plating on chitin media following the methods of
Caldera and Currie, and identiﬁed as Pseudonocardia sp. based on
multilocus sequencing.
10
Cultivation of Pseudonocardia sp. EC080529-01. Production
cultures of Pseudonocardia sp. EC080529-01 were grown on solid ISP-
2 medium (per liter: yeast extract, 4 g; malt extract, 10 g; glucose, 4 g)
in 12 Petri plates (150 × 20 mm, 1.2 L total) for 7 d at 30 °C. The
solid agar was cut into small cubes and soaked in EtOAc (1.2 L)
overnight. The EtOAc was ﬁltered and dried in vacuo to give the crude
EtOAc extract. The solid agar was re-extracted overnight with MeOH
(1.2 L), and the MeOH was ﬁltered and dried in vacuo to give the
crude MeOH extract. The crude EtOAc extract was dissolved in 90%
MeOH−H2O (20 mL) and passed through a C18 column, eluting with
additional 90% MeOH−H2O, in order to remove nonpolar
components. The eluent from this column was diluted with H2Ot o
give a ﬁnal MeOH concentration of 60%. This solution was passed
through another C18 column and washed with additional 60%
MeOH−H2O solution, followed by 100% MeOH. The 60%
MeOH−H2O fraction was puriﬁed by preparative HPLC using the
following gradient: 0−5 min, isocratic 20% CH3CN−H2O; 5−60 min,
linear gradient from 20% CH3CN−H2O to 100% CH3CN to give pure
4 (8.3 mg). The 100% MeOH fraction from this C18 column was
puriﬁed by preparative HPLC using the following gradient: 0−10 min,
isocratic 50% CH3CN−H2O; 10−60 min, linear gradient from 50%
CH3CN−H2O to 100% CH3CN to give pure 5 (3.5 mg). The crude
MeOH extract was dissolved in H2O and passed through an HP-20
column. The HP-20 column was washed with water to remove polar
components, and the compounds of interest were then eluted with
100% MeOH. The 100% MeOH fraction was dried in vacuo,
redissolved in 60% MeOH−H2O, and passed through a C18 column
to remove nonpolar components. The eluent from this column was
diluted with H2O to give a ﬁnal MeOH concentration of 30%. This
solution was passed through another C18 column and washed with
additional 30% MeOH−H2O, followed by 100% MeOH. The 100%
MeOH fraction from this C18 column was puriﬁed by reversed-phase
HPLC using the following gradient: 0−10 min, isocratic 10%
CH3CN−H2O + 0.1% formic acid; 10−60 min linear gradient from
Table 2. Cytotoxic Activities of 1−5 against HepG2 Cells
and Antibiotic Activities of 1−5 against P. berghei, E. coli, B.
subtilis, C. albicans, and S. cerevisiae
a
HepG2
P.
berghei E. coli B. subtilis
C.
albicans
S.
cerevisiae
compound
IC50
(μM)
IC50
(μM)
MIC
(μg/mL)
MIC
(μg/mL)
MIC
(μg/mL)
MIC
(μg/mL)
1 >100 38 >50 >50 >50 >50
2 >100 50 >50 >50 >50 >50
3 >100 >100 >50 >50 >50 >50
4 >100 18.5 >50 25 >50 >50
5 36.1 3.0 >50 3.13 >50 >50
aData represent the average of two experiments each performed in
triplicate. The MIC is deﬁned as the lowest concentration that gave
less than 5% of the maximum growth.
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formic acid to give pure 1 (2.0 mg), 2 (0.9 mg), and 3 (1.8 mg).
Pseudonocardone A (1): colorless solid (2.0 mg); [α]20
D −11 (c
0.02, MeOH); UV (MeOH) λmax (log ε) 310 nm (3.11), 279 (sh), 271
nm (3.59); 1H NMR (600 MHz, CD3OD) and 13C NMR (150 MHz,
CD3OD), see Table 1; (+)-HRESI m/z 497.1438 [M + H]+ (calcd for
C26H25O10, 497.1448).
Pseudonocardone B (2): yellow solid (0.9 mg); [α]20
D −2( c 0.02,
MeOH); UV (MeOH) λmax (log ε) 377 nm (3.52), 305 nm (3.87); 1H
NMR (600 MHz, CD3OD) and 13C NMR (150 MHz, CD3OD), see
Table 1; (+)-HRESI m/z 495.1295 [M + H]+ (calcd for C26H23O10,
495.1291).
Pseudonocardone C (3): orange solid (1.8 mg); [α]20
D −3( c 0.09,
MeOH); UV (MeOH) λmax (log ε) 403 nm (3.53), 314 nm (3.96); 1H
NMR (600 MHz, CD3OD) and 13C NMR (150 MHz, CD3OD) see
Table 1; (+)-HRESI m/z 511.1229 (calcd for C26H23O11, 511.1240).
Antibiotic Assays. The appropriate test organism was grown in a
5 mL culture overnight in either LB medium (for E. coli and B. subtilis)
or YPD medium (for C. albicans and S. cerevisiae)a t3 0°C. In each
case, the overnight culture was diluted with additional sterile medium
(LB or YPD) to an OD600 of 0.01. Compounds 1−5 were dissolved in
DMSO to give a concentration of 5 mg/mL and 2-fold serially diluted.
These solutions (1 μL) were added to the wells of a 96-well plate,
followed by the diluted culture of the test organism (99 μL) to give a
ﬁnal compound concentration ranging from 50 to 0.1 μg/mL. The
cultures were allowed to grow for 24 h at 30 °C before the OD600 was
measured using a plate reader. The MIC was deﬁned as the lowest
concentration that gave less than 5% of the maximum OD600. Each
antibiotic assay was performed in duplicate. Dynemicin A was used as
a positive control and gave MIC values against E. coli, B. subtilis, C.
albicans,a n dS. cerevisiae of 313, 0.16, 156, and 156 ng/mL,
respectively.
Cytotoxic Assay. Compounds were tested for activity against
HepG2 human hepatoma cells (ATCC) that were maintained in
DMEM (Invitrogen), 10% FBS (Sigma), and 1% antibiotic−
antimycotic (Invitrogen) in a standard tissue culture incubator (37
°C, 5% CO2). For assays, compounds 1−5 (in DMSO) were added in
triplicate to 15000 cells in a 384-well plate. The ﬁnal concentration of
DMSO was 1%, and compounds varied from 0 to 50 μg/mL. Cells
were incubated with the compounds for 2 days at 37 °C, and then liver
cell viability was assessed with CellTiter-Glo (Promega). The relative
signal intensity of each sample was evaluated with an EnVision
(PerkinElmer) system.
Liver-Stage P. berghei Assay. Liver-stage P. berghei assays were
performed using a luciferase-expressing sporozoite strain of P. berghei
ANKA. Parasites were obtained from dissection of Plasmodium-
infected Anopheles stephensi mosquitoes (New York University
Langone Medical Center Insectary). Malaria parasites (4000
sporozoites) were used to infect HepG2 cells (15000 cells) in a
384-well plate in the presence of compounds 1−5 in triplicate. The
ﬁnal concentration of DMSO was 1%, and compounds varied from 0
to 50 μg/mL. Cells were incubated with the compounds for 2 days at
37 °C, and then relative parasite load was determined after addition of
Bright-Glo (Promega). Data analysis for HepG2 toxicity and liver-
stage malaria activity was carried out using GraphPad Prism, and
curves were ﬁt with a standard inhibition dose−response curve to
generate an IC50 value. All statistical results are the mean IC50 value
averaged from two independent experiments. Atovaquone was used as
a positive control and gave an IC50 in blood stage assays of 0.3 nM.
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